Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes

Obesity

Volumn 20, Issue 7, 2012, Pages 1511-1518

  Bertoni, Alain G ^a   Wagenknecht, Lynne E ^a   Kitzman, Dalane W ^a   Marcovina, Santica M ^b   Rushing, Julia T ^a   Espeland, Mark A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN A1C;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIFESTYLE MODIFICATION; LOOK ACTION FOR HEALTH IN DIABETES; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SELF REPORT; WEIGHT REDUCTION;

BIOLOGICAL MARKERS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OBESITY; OVERWEIGHT; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RISK REDUCTION BEHAVIOR; TIME FACTORS; WEIGHT LOSS;

EID: 84862879894     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.296     Document Type: Article

References (42)

1. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;27:1879-1884.
2. Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699-703.
3. Bell DS. Heart Failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003;26:2433-2441.
4. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358:2148-2159.
5. Groenning BA, Nilsson JC, Sondergaard L et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 2002;143:923-929.
6. McDonagh TA, Holmer S, Raymond I et al. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail 2004;6:269-273.
7. Groenning BA, Raymond I, Hildebrandt PR et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal probrain natriuretic peptide concentrations in a large sample of the general population. Heart 2004;90:297-303.
8. Wang TJ, Larson MG, Levy D et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-663.
9. McKie PM, Rodeheffer RJ, Cataliotti A et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006;47:874-880.
10. deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol 2010;55:441-450.
11. Mehra MR, Uber PA, Park MH et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-1595.
12. Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600.
13. Rivera M, Cortés R, Salvador A et al. Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology. Eur J Heart Fail 2005;7:1168-1170.
14. Daniels LB, Clopton P, Bhalla V et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J 2006;151:999-1005.
15. Richards M, Nicholls MG, Espiner EA et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006;47:52-60.
16. Tsuruda T, Kato J, Sumi T et al. Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus. Vasc Health Risk Manag 2007;3:417-423.
17. Das SR, Drazner MH, Dries DL et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005;112:2163-2168.
18. Oreopoulos A, Ezekowitz JA, McAlister FA et al. Association between direct measures of body composition and prognostic factors in chronic heart failure. Mayo Clin Proc 2010;85:609-617.
19. Magnusson M, Melander O, Israelsson B et al. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004;27:1929-1935.
20. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005;48:156-163.
21. Deffur A, Ker JA, Rheeder P, Van Niekerk MM, Quinton SJ. NT-proBNP measurements in high-risk diabetic patients-a case series from Mamelodi (Gauteng). Cardiovasc J S Afr 2006;17:56-59.
22. Ryan DH, Espeland MA, Foster GD et al.; Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610-628.
23. The Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374-1383.
24. Bray G, Gregg E, Haffner S et al.; Look Ahead Research Group. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab Vasc Dis Res 2006;3:202-215.
25. Heshka S, Ruggiero A, Bray GA et al.; Look AHEAD Research Group. Altered body composition in type 2 diabetes mellitus. Int J Obes (Lond) 2008;32:780-787.
26. Olsen MH, Hansen TW, Christensen MK et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005;46:660-666.
27. Costello-Boerrigter LC, Boerrigter G, Redfield MM et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345-353.
28. Tildesley HD, Aydin CM, Ignaszewski A et al. Sulfonylurea therapy is associated with increased NT-proBNP levels in the treatment of type 2 diabetes. Int J Cardiol 2007;115:312-317.
29. Cosson E, Nguyen MT, Pham I et al. N-terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. Diabet Med 2009;26:872-879.
30. Park SJ, Cho KI, Jung SJ et al. N-terminal pro-B-type natriuretic Peptide in overweight and obese patients with and without diabetes: an analysis based on body mass index and left ventricular geometry. Korean Circ J 2009;39:538-544.
31. St Peter JV, Hartley GG, Murakami MM, Apple FS. B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. Clin Chem 2006;52:680-685.
32. Chainani-Wu N, Weidner G, Purnell DM et al. Relation of B-type natriuretic peptide levels to body mass index after comprehensive lifestyle changes. Am J Cardiol 2010;105:1570-1576.
33. Chen-Tournoux A, Khan AM, Baggish AL et al. Effect of weight loss after weight loss surgery on plasma N-terminal pro-B-type natriuretic peptide levels. Am J Cardiol 2010;106:1450-1455.
34. Lim HS, Patel JV, Nadar S, Hughes EA, Lip GY. Comparison of brain natriuretic peptide and left ventricular diastolic function determined by tissue Doppler in patients with diabetes mellitus, patients with hypertension without diabetes, and in healthy subjects. Am J Cardiol 2005;95:905-908.
35. Sambanis C, Tziomalos K, Kountana E et al. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol 2008;45:23-30.
36. Turkmen KY, Guvener DN, Yildirir A et al. Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus. Acta Diabetol 2007;44:149-156.
37. Lavie CJ, Milani RV, Ventura HO, Romero-Corral A. Body composition and heart failure prevalence and prognosis: getting to the fat of the matter in the "obesity paradox". Mayo Clin Proc 2010;85:605-608.
38. Chang AY, Abdullah SM, Jain T et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol 2007;49:109-116.
39. Saenger AK, Dalenberg DA, Bryant SC, Grebe SK, Jaffe AS. Pediatric brain natriuretic peptide concentrations vary with age and sex and appear to be modulated by testosterone. Clin Chem 2009;55:1869-1875.
40. Grossmann M, Gianatti EJ, Zajac JD. Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010;17:247-256.
41. Harvie MN, Pegington M, Mattson MP et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) 2011;35:714-727.
42. McKie PM, Cataliotti A, Lahr BD et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol 2010;55:2140-2147.